US 11,969,503 B2
Methotrexate composition
Carl Tierney, Leeds (GB); Stacey Powell, Leeds (GB); Peter Braybrooke, Leeds (GB); and Geraint Jones, Leeds (GB)
Assigned to Rosemont Pharmaceuticals Ltd, Leeds (GB)
Filed by Rosemont Pharmaceuticals Ltd., Leeds (GB)
Filed on Sep. 9, 2021, as Appl. No. 17/470,131.
Application 17/470,131 is a continuation of application No. 16/839,178, filed on Apr. 3, 2020, granted, now 11,116,724.
Application 16/839,178 is a continuation of application No. 16/266,305, filed on Feb. 4, 2019, granted, now 10,610,485, issued on Apr. 7, 2020.
Application 16/266,305 is a continuation of application No. 15/821,242, filed on Nov. 22, 2017, granted, now 10,231,927, issued on Feb. 4, 2020.
Application 15/821,242 is a continuation of application No. 15/019,244, filed on Feb. 9, 2016, granted, now 9,855,215, issued on Jan. 2, 2018.
Application 15/019,244 is a continuation of application No. 13/733,031, filed on Jan. 2, 2013, granted, now 9,259,427, issued on Feb. 16, 2016.
Claims priority of application No. 1200192 (GB), filed on Jan. 6, 2012.
Prior Publication US 2021/0401742 A1, Dec. 30, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 9/08 (2006.01); A61K 9/00 (2006.01); A61K 31/519 (2006.01); A61K 47/02 (2006.01); A61K 47/12 (2006.01); A61K 47/14 (2017.01)
CPC A61K 9/08 (2013.01) [A61K 9/0053 (2013.01); A61K 9/0095 (2013.01); A61K 31/519 (2013.01); A61K 47/02 (2013.01); A61K 47/12 (2013.01); A61K 47/14 (2013.01)] 20 Claims
 
1. A methotrexate composition for oral administration, said composition consisting of:
methotrexate or a salt thereof;
one or more buffer agents to adjust the pH of the composition, wherein the pH of the composition is 6 to 7;
one or more preserving agents;
one or more agents selected from flavouring compounds and sweetening agents; and
purified water.